During the past decades, pharmacological treatment of symptomatic benign prostatic hyperplasia (BPH) has become a fairly established modality. Approaches include blockade of aadrenoreceptors and suppression of androgens. Patients eligible for drug treatment are those with mild to moderate symptoms of BPH and no strong indications for surgery.
a-Receptor blockers generally improve urinary symptoms and peak urinary flow rates 2 to 4 weeks after introduction of therapy. Because of minor adverse effects, selective aI-blockers are preferred over nonselective drugs. Prazosin, terazosin and alfuzosin are extensively studied and widely used in BPH treatment. Terazosin might be preferred to prazosin and alfuzosin because it can be administered once daily, but a disadvantage is higher cost. Doxazosin and tamsulosin (amsulosin; YM 617) are drugs currently under clinical investigation in the treatment of BPH.
Antiandrogen therapy induces reduction in prostate volume and relief in symptoms of bladder outlet obstruction. However, the only drug which seems to be of major interest in BPH treatment is finasteride. Other drugs [gonadotrophin-releasing hormone (GnRH) agonists, progestogens and flutamide] are associated with frequent and sometimes severe adverse effects, such as impotence, flushing and loss of libido. Finasteride has fewer adverse effects and is well tolerated, but needs to be administered for at least 6 to 12 months to obtain maximum effect.
Future approaches in medical treatment ofBPH might be combination therapy of aI-blockers and finasteride.
Benign prostatic hyperplasia (BPH) is the most common cause of voiding dysfunction in men. The prevalence of BPH increases with age. As the average age of the population increases, an increasing prevalence of BPH is expected.
BPH is a heterogeneous disease which may be asymptomatic, but often becomes symptomatic from the fifth decade of life. Because the prostate surrounds the urethra, urinary symptoms are often the signs of prostatic hyperplasia. Poor stream and bladder emptying, terminal dribbling, increased abdominal and intravesical pressure during voiding and hesitancy are referred to as obstructive symptoms of BPH. Urge, nocturia and increased diuria are by tradition called the irritative symptoms of BPH. However, the symptomatology of BPH often varies and large intra-and interindividual variation in symptoms is often seen. Other patients present with urinary tract infections, haematuria or acute urinary retention. Rarely, patients present with chronic renal insufficiency.
Transurethral resection of the prostate (TURP) is the standard treatment of BPH. In 1988 in the US, approximately 400000 transurethral resections of the prostate were performed (Holtgrewe et al.1989 ). TURPcomprisedmorethan24%ofurol-ogists' workload and 38% of all major surgery performed by urologists, accounted for 1.4% of total Medicare charges, and was second only to cataract extraction as the most costly major operation covered by Medicare. The estimated economic burden of treating BPH in the UK in 1990 was between £62 million and £91 million, excluding the intangible costs (Drummond et al. 1993) . Since the introduction of effective pharmacological alternatives to TURP, the surgery rate has been reduced, but surgical treatment of BPH is still the predominant therapy in terms of healthcare costs.
Despite substantial social, economic and scientific interest, relatively little is known about the natural history and aetiology of BPH. It is known that a combination of aging and androgens is needed in the development of BPH. The disorder is almost unknown in castrated men and seldom seen in men younger than 40 years. By the eighth decade of life, 85% of men are found to have histological evidence of BPH at post mortem (Berry et al. 1984) . No known prophylactic treatment eXists and all treatment, both surgical and pharmacological, is symptomatic. Because many of the clinical manifestations of BPH are related to intravesical obstruction, treatment is directed towards relieving bladder outlet obstruction.
Until recently, drug treatment of BPH was inadequate because of insufficient knowledge of drug actions on the prostate. Since Caine and colleagues (1975a) described the distribution of a-and ~ receptors in the smooth muscles of the prostate, the search for drugs relaxing prostatic smooth muscle tone has expanded. With a reduction in prostatic smooth muscle tone mediated via blockade of aadrenoceptors, intraurethral pressure declines (Abrams et al. 1982) , thus reducing the bladder pressure required to allow urine to pass through the urethra.
The development of new drugs with few adverse effects which modulate androgen activity has expanded the spectrum of medication in BPH treatment. These drugs induce prostatic volume reduction and therefore reduce urethral obstruction.
In spite of promising results using a-receptor blockers or androgen-modulating drugs there is still a long way to go before we can identify 'the prostatic pill' which would be an equal substitute for surgery. Not all patients experience benefit from pharmacological treatment of BPH and a drug substituting for complete resection or eriucleation of the prostate seems unrealistic. Prostatectomy will probably always have a place in BPH treatment and the future challenge will be to satisfy patients with symptomatic BPH so that more effec-tive treatment is offered with the least associated morbidity (Lepor 1989) .
This article is a review of the current pharmacological treatment of BPH based on historical and current treatment. Recommendations for appropriate drug treatment of BPH are given.
a-Receptor Blockers
BPH-related bladder outlet obstruction is believed to consist of two components: a dynamic part and a static part. The dynamic part is caused by the tone of the prostate, especially the prostate capsule smooth muscle which is innervated and regulated by the adrenergic component of the autonomic nervous system. Roughly one-third of the tissue within the prostatic capsule is fibromuscular, anatomically and functionally related to the bladder and urethra (McNeal 1981) . A change in the prostatic capsular fibromuscular tone will reduce the pressure within the prostatic urethra and theoretically improve urine flow.
The static component of BPH-related bladder outlet obstruction is caused by the pressure of the prostatic adenomatous hyperplasia which obstructs urine outlet. A release of this obstruction is accomplished by surgery (incision, TURP or stents) or by inducing shrinkage of the prostate adenoma by androgen-modulating drugs or hyperthermia. Caine et al. (1975a) described the distribution of a-and ~-receptors in human prostate adenoma, prostate capsule and bladder neck from patients undergoing retropubic prostatectomy. Prostate tissue was harvested and a larger contractile effect in the prostate capsule than in the adenoma was reported. The prostate adenoma, prostate capsule and bladder neck showed high concentrations of a-receptors but low concentrations of ~-receptors. Further investigations of a-receptor density have demonstrated a higher density of a-receptors in the prostate and bladder neck than in the bladder (Shapiro & Lepor 1987) .
a-Receptor blockers have been proven to change the tone of the prostatic capsule (and adeDrugs 47 (1) 1994 noma), decreasing the pressure in the prostatic part of the urethra and bladder neck without affecting bladder pressure (Khanna & Gonick 1975) , and this is the theoretical rationale for using a-receptor blockers in BPH treatment.
In 1976, Caine et al. published the results of administering a-receptor blockers to patients with BPH. They concluded that a-receptor blockers had clinical effects in patients with symptoms of BPH or acute urinary retention. Numerous clinical trials have since evaluated the effects of various a-receptor blockers in patients with BPH and today treatment of the condition with a-blockers is well established.
a-Blockers in the treatment of BPH can be divided into two groups: ai-receptor blockers and nonselective blockers. Generally, treatment with a-receptor blockers causes a 50% increase in urinary flow rates (Lepor 1990) . Changes in urinary symptoms are difficult to estimate because of major differences between the study protocols used, as well as the large placebo response often seen in clinical studies. Symptom scores have not been used in all clinical trials and, in those that do use such a scoring system, the score itself is often not validated. Nevertheless, almost all studies evaluating a-receptor blockers in BPH patients conclude that there is an improvement in both urodynamics and symptoms.
Both nonselective and al-adrenoceptor blockers are used in the treatment of BPH. The reported adverse effects in different drugs varies. Generally, ai-receptor blockers seem to have a smaller incidence and lower severity of adverse effects than the nonselective agents. Lepor (1990) stated that the effect of a-receptor blockers in BPH treatment is related to ai-receptor blockade whereas the adverse effects are related to blockade of a2-receptors. Recently, new subtypes of prostate ai-receptors -alA and (llB -have been discovered (Lepor et al. 1993) . Preliminary isometric tension studies indicate that the tissue tension elicited by phenylephrine is mediated primarily by the (lIB-receptor in the prostate. The adverse effects arising from a-blocker therapy may be caused by blockade of the alA-receptors located in vascular and cerebral tissue. Theoretically, a new selective a-receptor blocker blocking only alB-receptors would minimise the adverse effects associated with a-receptor blockade and achieve therapeutic response in BPH patients (table I).
Phenoxybenzamine

Pharmacology
Phenoxybenzamine is a nonselective a-receptor blocker with high affinity for both al-and alreceptors, and was the first a-blocker used in the treatment of BPH. The pharmacokinetics of phenoxybenzamine are not well understood, but the half-life is <24 hours and absorption is 20 to 30% after oral administration (Hoffman & Lefkowitz 1990 ).
Efficacy
In 1977, Boreham et al. reported the results of a nonblinded study including 27 patients with BPH treated with phenoxybenzamine lOmg twice daily. 18 of 27 patients completing the 7-day trial had improved urinary symptoms, while 9 patients ex-69 perienced no improvement. Ten patients had increased urinary flow rates. Caine et al. (1978) reported a double-blind placebo-controlled study evaluating the effects of phenoxybenzamine in 50 patients, 49 of whom completed the study. 24 patients were given phenoxybenzamine lOmg twice daily for 15 days and 26 patients received placebo. 87.5% of the patients in the phenoxybenzamine-treated group showed an average increase from baseline in peak urinary flow rates of 6.2 mllsec, compared with 1.2 mllsec in 18.5% of the placebo group. No change in postvoided residual urine volumes were observed between the two groups. Comparing both groups, Caine et al. found a significant improvement in diuria and nocturia in the phenoxybenzaminetreated group. Adverse effects were reported in 11 phenoxybenzamine recipients and in one patient in the control group. The main complaints were tiredness and dizziness, but impaired ejaculation and nasal stuffiness were also reported. No patient stopped treatment because of adverse effects.
A 2-phase study with phenoxybenzamine 10mg twice daily was reported by Abrams et al. (1982) . The first phase was a double-blind placebo-controlled study including 41 patients with symptoms of BPH treated for 4 weeks. The second phase was an open-label study involving another 20 patients who were all treated with phenoxybenzamine. Compared with the placebo group, there was an overall symptomatic improvement in phase 1 for patients treated with phenoxybenzamine. The severity of hesitancy and slow stream was significantly reduced, whereas symptoms of frequency, nocturia, urgency and incontinence were not significantly reduced by phenoxybenzamine treatment. Urodynamic investigation showed a significant increase in peak urinary flow rates from 7.2 mllsec at baseline to 10.3 mllsec in phenoxybenzamine recipients, versus no significant improvement in urinary flow rates in placebo-treated patients. Phenoxybenzamine significantly reduced intraurethral pressure at the prostatic plateau, whereas cystometric evaluation demonstrated no changes in bladder pressure compared with baseline.
Of 61 patients, 4 withdrew; 1 placebo-and 3 phenoxybenzamine-treated patients. The main complaint in the phenoxybenzamine group was dizziness and postural hypotension.
Tolerability
The most commonly reported adverse effects of phenoxybenzamine are postural hypotension associated with tachycardia and arrhythmias, tiredness and dizziness. Reversible inhibition of ejaculation and aspermia are noticed among patients with BPH receiving phenoxybenzamine.
Dosage and Administration
The recommended dosage of the drug to treat BPH is 5 or lOmg twice daily. However, with the development of new selective aI-receptor blockers with fewer adverse effects, and because of associated intestinal malignancy in rats, phenoxybenzamine is now considered an obsolete drug in the treatment of BPH.
Prazosin
Pharmacology
Prazosin is an aI-receptor blocker which acts by competitive inhibition of noradrenaline (norepinephrine) receptors in the smooth muscle fibres in arterioles and veins. This causes a decrease in total peripheral resistance due to reduction of tone in peripheral vessels, and no secondary increase in heart rate. Prazosin probably exerts its effect on the prostate in the same way, reducing the pressure on the urethra. It is proposed that prazosin may have some action on the central nervous system as well (Cubbeddu 1988) .
70% of an oral dose of prazosin is absorbed, and the peak plasma concentration is reached in 1 to 3 hours. The drug is 95% bound to plasma proteins. Prazosin has a half-life of 3 hours, a bioavailability of approximately 70%, and the duration of action is 4 to 6 hours (Cubbeddu 1988; Hoffman & Lefkowitz 1990 ).
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Efficacy
In 1983, Hedlund et al. presented a doubleblind, crossover study in 20 patients with BPH treated for 2 weeks with placebo and 2 weeks with prazosin. The initial prazosin dose was Img, increasing to 4mg divided in 2 daily doses. There was a significant increase in maximal and mean urinary flow rates, as well as a reduction in postvoided residual urine volume and obstructive symptoms during prazosin treatment. After 2 weeks of prazosin treatment the average urinary flow rate increased from 2.6 to 3.7 ml/sec (p < 0.01) and maximal urinary flow rates increased from 4.9 to 6.9 mllsec (p < 0.01). Voiding pressure, bladder capacity and irritative symptoms did not change significantly. Kirby et al. (1987) reported a double-blind, parallel group study of prazosin versus placebo in 80 patients. Prazosin was titrated to 2mg within 8 days and the trial lasted 4 weeks. 25 patients were excluded or withdrawn from the study, 12 in the prazosin-treated group and 13 in the control group. No patients in the prazosin group were withdrawn because of adverse effects. A significant improvement in peak urinary flow rates from 8 ml/sec at baseline to 13 mllsec was seen in prazosin recipients (p < 0.005). In the placebo group, peak urinary flow rates were unchanged. No statistical change in postvoided residual urine volumes or voiding pressures were reported. Voiding diary data showed a statistically significant difference between the two groups, with prazosin-treated patients having a more pronounced reduction in urinary frequency than those in the placebo group (p < 0.01).
A further double-blind trial by Yamamaguchi et al. (1990) reported the results of treating patients with prazosin 0.5mg 3 times daily initially, then titrating up to Img 3 times daily, or a fixed combination of L-alanine 100mg, L-glutamic acid 265mg and aminoacetic acid 45mg (Paraprost@). The trial lasted for 3 weeks. A total of 156 patients were included; 77 prazosin-treated patients and 79 patients receiving Paraprost@. One patient in each group dropped out due to adverse effects.
There was a significant and similar improvement in urinary symptoms (hesitancy, prolonged voiding, slow stream, strain voiding and incomplete bladder evacuation) in both groups during treatment. No significant differences between the two groups with respect to frequency, nocturia and postvoided residual urine volume were reported either. A significant increase in maximal and mean flow rates compared with baseline observations was observed in prazosin recipients, but not in the Paraprost® group. Adverse effects reported by prazosin-treated patients in this trial included blurred vision, gastric discomfort, nausea and dizziness.
Tolerability
The so-called first dose phenomenon, manifested by marked postural hypotension and syncope after first time administration, is the most common adverse effect of prazosin. The risk of this effect is reduced by slowly increasing the dosage and administering the drug at bedtime. Nonspecific adverse effects such as headache, dizziness, drowsiness and nausea have also been described.
Dosage and Administration
Prazosin must be administered 2 or 3 times daily at a dose of 2mg to be effective in the treatment of BPH.
Today, prazosin is used worldwide in BPH treatment, but because of its short half-life the drug is not preferred compared with terazosin and doxazosin. However, the cost of prazosin is lower than for other (Xl-receptor blockers with longer half-lives, which makes some physicians and patients prefer this drug.
Terazosin
Pharmacology
Terazosin is the most extensively studied (Xl-receptor blocker for the treatment of BPH . Its therapeutic action is similar to that of prazosin. It is a structural analogue of prazosin but is less potent, with an affinity for (Xl-receptors which is 2.5 lower than that of prazosin (Kyncl 1986 ). The affinity ofterazosin for (Xl-receptors is 71 200 times greater than its affinity for the (X2-subtype.
Pharmacokinetic properties are the major distinctions between prazosin and terazosin. The halflife of terazosin is 12 hours, the bioavailability is >90% and peak of action is seen 1 to 1.7 hours following oral administration. The effects of the drug last approximately 18 hours. Less than 10% of the drug is excreted unchanged in the urine (Cubbeddu 1988; Hoffman & Lefkowitz 1990 ). Dunzendorfer (1988) reported the first results of terazosin in BPH treatment. The study included IS patients who had a 4-week placebo run-in period followed by 6 months' single-blind treatment. The dosage was increased to IOmg once daily.
Efficacy
After 4 months of treatment with terazosin, a significant increase of 1.8 mUsec in peak urinary flow rates and 2 mUsec in mean urinary flow rates was noticed compared with baseline values. Obstructive and total symptom scores decreased significantly. However, no significant improvement in irritative score was found. Adverse effects such as mild headache, dizziness, asthenia and dysuria were reported.
Subsequently, Lepor et al. (1990) reported a dose titration study of terazosin which 39 patients completed. The study was of open-label design, and uroflowmetry and symptom scores, including global assessment of urinary symptoms, were evaluated. Terazosin was administered at 1, 2 and Smg for 2, 2 and 4 weeks, respectively.
There was a significant dose-related increase in peak urinary flow rates from a baseline value of 8.S mUsec to 12.1 mUsec with terazosin Smg. Compared with baseline, a significant improvement in obstructive symptoms of 63% was reported. The irritative symptom score improved significantly in 3S% of patients. 67% of patients rated symptom improvement after treatment as markedly improved, 11 % slightly improved, and 9% unchanged. After the primary study, the patients were given the opportunity of continuing terazosin treatment, undergoing prostatectomy or clinical observation. 6S% elected to continue terazosin treat-ment. In these patients no further improvement in urinary flow rates or symptoms was noticed at 4 and 10 months' follow-up.
Five patients did not complete the primary study due to development of adverse reactions such as erectile dysfunction, tiredness, mild headache, palpitations, nasal congestion and hypotension.
Lepor's group then reported a multicentre study of terazosin in 285 patients with BPH receiving either placebo or terazosin 2, 5 or lOmg once daily for 16 weeks (Leporet al. 1992 ).237 patients completed the study. All patients treated with terazosin experienced a significant decrease in symptoms (irritative, obstructive and total) compared with baseline values. Peak and mean urinary flow rates increased significantly in all terazosin recipients compared with baseline. The groups receiving 5 and 10mg had an increase in peak urinary flow rates of 1.7 and 3 mVsec, respectively. The improvement in urinary flow rates and symptom scores did not reach a plateau, suggesting that further improvement might be achieved by increasing the dosage ofterazosin. No significant changes in urinary flow rates were observed in the placebo group. Overall adverse effects were minor, but a higher frequency of asthenia and dizziness was seen in the terazosin-treated patients. The number of patients with postural hypotension was significantly higher with terazosin treatment.
A placebo-controlled multicentre study of 132 patients, 81 of whom completed the full trial, was reported by Lloyd et al. (1992) . The patients had a 4-week placebo run-in followed by 8 weeks' double-blind treatment with placebo or terazosin 2, 5 or 10 mg/day. A significant change in obstructive and irritative score was observed both in the placebo-and actively treated groups, but no significant changes were observed between the two groups. Compared with baseline values, an improvement in urinary flow rates and postvoided residual urine volumes was observed in both the placebo and terazosin recipients. Again, no significant differences could be demonstrated between the two groups. Few adverse effects were reported, and terazosin was well tolerat,ed, with dizziness and headache as the major complaints. Fabrisius and Hannaford (1992) reported a double-blind placebo-controlled study of terazosin lOmg once daily in 57 patients. A significant increase in mean peak urinary flow rates and mean urinary flow rates in the terazosin-treated group of 54% (from 7.76 to 11.92 mVsec) and 55% (from 4.9 to 7.59 mVsec), respectively, was noted. Follow-up on 12 and 9 patients treated with terazosin 5mg daily for 1 and 2 years, respectively, failed to demonstrate any loss of efficacy.
Adverse effects were reported in 30% (17 of 57) of the patients, with headache, asthenia, hypotension and dysuria as the most common. None of the adverse events necessitated dose reduction during the double-blind part of the study, but during the long term follow-up, the dosage of terazosin was reduced from 10 to 5mg to minimise or prevent dizziness.
Tolerability
The adverse effects of terazosin are much like the adverse effects of prazosin.
Dosage and Administration
The typical dosage of terazosin is Img orally at bedtime, titrated to 2mg and then 5 or 10mg as the final dose depending on response and tolerability.
Alfuzosin
Pharmacology
Alfuzosin is a selective a-receptor blocker with 1000-fold greater affinity for al-than for a2-receptors (Bourin 1989) . The half-life of alfuzosin is 5 hours following oral administration and peak plasma concentration is reached after approximately 1.5 hours ). The drug is 90% protein bound, and has a bioavailability of 64%.
Efficacy
The first clinical study of alfuzosin in BPH was reported by Ramsey et al. in 1985 . 31 patients with symptoms of BPH randomly received alfuzosin 9 or 12mg daily, or placebo. After 12 weeks of treat-ment, all alfuzosin recipients had improved micturition frequency compared with baseline, whereas no improvement occurred in the placebo group. Urinary flow rates and postvoided residual urine volume were unchanged compared with pretreatment values. None of the patients withdrew because of adverse effects. Jardin et al. (1991) reported the efficacy of alfuzosin in a multicentre, placebo-controlled study in 518 patients with symptoms of BPH, who received alfuzosin 7.5 or 10 mg/day, or placebo for 6 months. Patients were evaluated using a symptom score, urinary flow rates and postvoided residual urine volume. 162 patients withdrew from the study -70 alfuzosin and 92 placebo recipients.
Total symptom score decreased in both groups, but reached significance only in the alfuzosintreated patients. Analysis of symptoms revealed that alfuzosin was significantly more effective than placebo for all symptoms except dribbling. After 6 months' treatment with either alfuzosin or placebo, there were improvements in peak urinary flow rates (mean 12.1 to 13.5 mllsec vs 12.0 to 13.3 mllsec) and mean urinary flow rates (mean 6.6 to 7.5 mllsec vs 6 to 6.6 mlIsec). However, only mean urinary flow rate was significantly improved in the a1fuzosin-treated patients after 6 months. There was a significant improvement in residual volume with alfuzosin compared with placebo treatment.
51 patients (27 in the alfuzosin and 24 in the placebo groups) discontinued treatment because of adverse effects. Dizziness, headache and postural hypotension were the most common adverse effects. They were more frequently associated with alfuzosin only during the first 2 weeks of therapy.
The preliminary (3-month) results of a large, open-label study assessing the efficacy of alfuzosin 7.5 mg/day in 7093 patients with BPH symptoms have been reported recently (Lukacs et al. 1993) . Urinary symptoms and quality of life were evaluated using a specific questionnaire. After 3 months of treatment, both of these parameters had improved significantly compared with baseline. Adverse effects were reported in 2.6% of the patients, and were possibly due to vasodilator 73 properties in the majority of patients. These preliminary results suggest that alfuzosin may improve overall quality of life in men with BPH.
Tolerability
Alfuzosin is as well tolerated as prazosin and terazosin. Adverse effects are related mainly to vasodilatation.
Dosage and Administration
The typical dosage of alfuzosin is 7.5 or 10 mg/day, orally, in 3 divided doses.
Doxazosin
Pharmacology
Doxazosin is a structural analogue of prazosin and it is also a high affinity (ll-receptor blocker. Its affinity for (ll-receptors is 400 times greater than its affinity for (l2-receptors.
It differs from prazosin with respect to pharmacokinetics. The half-life of doxazosin is 20 hours, and the duration of action is 18 to 36 hours, with maximum effects obtained 6 hours after oral administration. The drug is 99% protein bound and the metabolites of doxazosin are mainly excreted in the faeces, with less than 5% excreted unchanged in the urine. The bioavailability and metabolism of doxazosin and prazosin are equivalent (Cubbeddu 1988; Hoffman & Lefkowitz 1990 ).
Efficacy
Doxazosin is used extensively in the treatment of hypertension. Numerous clinical trials investigating the drug in BPH treatment are underway, but most have not yet been published. Nevertheless, preliminary results have been reported (Fawzy et al. 1993; Gillenwater 1993) . Gillenwater (1993) compared doxazosin with placebo in a double-blind manner for 16 weeks in 100 patients with normal blood pressure and BPH. The doxazosin-treated patients were titrated to the maximally efficacious and/or maximally tolerated dose of medication; 88% received 8mg.
A significant increase in peak urinary flow rate of 2.9 mllsec versus baseline was revealed with doxazosin, compared with a nonsignificant in-crease of 0.9 mllsec with placebo. Mean flow rates also improved significantly with doxazosin. Troublesome symptoms were evaluated using a questionnaire (maximum score = 45) and a symptom questionnaire generated by the American Urological Association (AUA) [maximum score = 30]. The irritative score improved 4.7 points in doxazosin recipients vs 2.1 in the placebo group (p < 0.05).
Similarly, the AUA-based questionnaire score improved 5.7 points in the doxazosin group vs 2.5 points in the placebo-treated patients.
The most common reported adverse effects were dizziness, headache and fatigue; 44% of the doxazosin recipients reported adverse effects vs 30% in the placebo group. Seven doxazosintreated patients and one placebo-treated patient discontinued due to adverse effects. Hypotension was noticed in 2 of the doxazosin group, who discontinued the study. Fawzy et al. (1993) reported a double-blind, placebo-controlled, multicentre trial of 216 patients with BPH and mild to moderate essential hypertension. The patients received doxazosin 2, 4, 8 or 12 mg/day or placebo for 16 weeks.
Significant reductions in obstructive symptom score of3.6 and 3.3, respectively, were found in the patients receiving doxazosin 4 and 8mg. However, irritative symptoms did not improve significantly. Increases in peak urinary flow rates were 2.5, 4.6 and 3.2 mllsec with doxazosin 4, 8 and 12mg dosages, respectively, which were significant compared with placebo. No hypertensive crises were seen, and 5 patients receiving the active drug experienced hypotension. The reported adverse effects were dizziness, headache and fatigue, affecting 48% of doxazosin-treated patients and 34% of the placebo group.
1.6 Tamsulosin (Amsulosin; YM 617) Tamsulosin (Amsulosin; YM 617) is a recently synthesised potent (Xl-receptor blocker. Honda and Nakagawa (1986) reported the effects of tamsulosin on rabbit urinary tract and prostate, and found tamsulosin was able to antagonise phenylDrugs 47 (1) 1994 ephrine-induced contractions in a competitive manner. Kawabe and Niijima (1987) published the first clinical trial on tamsulosin, treating 77 patients with BPH with tamsulosin 0.2 or O.4mg daily for 14 days. No control or placebo groups were used. A significant decrease in postvoided residual urine volume and an increase of 2.3 mlIsec in mean and 3 mllsec in peak urinary flow rates were found in the group given the higher dosage compared with baseline values. In the group receiving the lower dosage, significant decreases in postvoided residual urine volume and mean urinary flow rates, but not in peak urinary flow rates, were noticed. A significant reduction in the severity of nocturia frequency from 2.8 to 2 times (0.2mg) and from 3 to 2 times (O.4mg) was found. No significant change in daytime frequency was noticed. Overall, about 80% of the patients had improvement in symptoms during 2 weeks' treatment with tamsulosin.
Two patients were reported to have slight adverse effects including bitter taste in the mouth and gastrointestinal discomfort. One patient showed elevated liver enzyme values after 14 days of taking tamsulosin O.4mg.
Later, Kawabe et al. (1990) reported the effects of tamsulosin in 270 patients in a double-blind study. After 2 weeks on placebo the patients were randomly assigned to receive either placebo or amulosin 0.1, 0.2 or O.4mg for 4 weeks. 231 patients completed the study. The severity of symptoms (nocturia, urgency, hesitancy, intermittency, terminal dripping and dysuria) decreased in the group given the highest dosage (p < 0.01), and postvoided residual urine volume decreased in those receiving tamsulosin 0.2 or O.4mg (p < 0.05).
Compared with baseline values, peak urinary flow rates were significantly improved in all groups during tamsulosin treatment. No significant changes in peak urinary flow rates were noticed in the placebo group. Adverse effects such as gastrointestinal discomfort and nausea were reported in 5 of the tamsulosin-treated group and none in the placebo group.
Summary of a-Receptor Blocker Treatment
Urodynamic measures are often described and referred to as objective parameters. Modest improvements in urinary flow rates are seen in most studies investigating a-blockers, and a more dramatic improvement in flow was noticed in several studies. Residual urine tends to be decreased by therapy, but this effect may be nearly as great with placebo. However, a great intra-and interindividual variation in urodynamics, such as peak flow rates and postvoided residual urine volume exists. The importance of using postvoided residual volume as a parameter in clinical trials is further debatable (Bruskewitz et al. 1982) .
We could speculate and wonder about the importance of assessing so-called hard data as outcome parameters in that the most often used indication for surgical therapy for BPH is symptomatic of bladder outlet obstruction . BPH is a heterogeneous disease and typically patients experience a wide range in the spectrum and severity of symptoms. Evaluating the change in symptoms during and after treatment is crucial. A self-administered, validated questionnaire that includes quality of life assessment is essential, but most often a non validated questionnaire was used in the studies investigating a-blockers.
Studies on selective at-receptor blockers in the treatment of BPH are not exhaustive in that they tend to be of short duration and evaluate few patients. Further, the majority of the studies were not blinded or placebo-controlled, and assessment of quality of life as well as irritation caused by urinary symptoms was seldom performed. For instance, a patient who is mainly bothered by nocturia may, after institution of therapy, not experience great relief if he still has to vbid 5 to 6 times each night, despite significant regression in symptom score and improvement in peak urinary flow rates. Sexual functioning was seldom evaluated in clinical trials. This area is of major interest in that some a-receptor blockers cause decreased, impaired or retrograde ejaculation. Another concern is that the 75 criteria for selecting BPH patients for treatment were seldom characterised or stated.
Androgen-Suppressing Therapy
The effects of anti androgen therapy on BPH were investigated a century ago. White (1895) and Cabot (1896) noted that approximately 85% of patients with BPH experienced marked regression in severity of symptoms after castration. However, the results of White and Cabot could not be confirmed in other trials and castration as a treatment modality for BPH fell into disfavour.
The pharmacological management of BPH has gained increased interest since the development of antiandrogen drugs. Trials have established that testosterone and other androgens are needed for the development of BPH. Castration in men and dogs has resulted in regression of prostatic enlargement (Lepor 1989; Peters & Walsh 1987) and numerous trials using anti androgen drugs have shown improvement in urinary flow rates and BPH-related symptoms. There seems to be no difference in the serum levels of testosterone in age-matched men with and without BPH (Bartsch et al. 1979 ). Androgens presumably provide the hormonal environment needed for development of BPH, and the observation that androgen suppression induces prostatic shrinkage is the basis for using androgensuppressing drugs in BPH patients (Lepor 1989) .
Testosterone is synthesised by the testes and by the adrenal cortex, and is regulated by negative feedback. Gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH)] promotes the release of luteinising hormone (LH) from the anterior pituitary gland which stimulates the Leydig cells in the testes and the adrenal cortex (zona fasciculate and zona reticularis) to produce testosterone. Blockade or inhibition of any of the steps in this regulatory system will reduce the serum testosterone level, causing a secondary reduction in prostate volume within 6 months.
Within the prostate gland, testosterone is converted to dihydrotestosterone (DHT) by the enzyme Sa-reductase. High levels of Sa-reductase are found only in the prostate gland, genital skin and frontal scalp. Whereas testosterone is the main physiological androgen in the serum, DHT is the major physiologically active androgen in the prostate gland. DHT is involved and needed for the enlargement of the prostate. Blocking 5a-reductase activity has been proven to reduce prostatic size and prostatic symptoms (Gormley et al. 1992; Stoner 1990) [table II] .
GnRH Agonists
GnRH agonists [nafarelin, buserelin, goserelin and leuprorelin (leuprolide)] all reduce the release of LH by desensitising the GnRH receptors in the anterior pituitary gland during continuous administration. GnRH agonists are all able to reduce the production of testosterone, induce shrinkage of the prostate volume by 29 to 46% and reduce the severity of urinary symptoms of BPH (Gabrilove et al. 1989; Keane et al. 1988; Peters & Walsh 1987) . Unfortunately, these drugs have adverse effects such as impotence and flushing, which stopped a majority of patients from taking the drugs. GnRH agonists are of inconsequential significance in BPH treatment, but of major importance in the treatment of patients with advanced prostatic cancer.
Progestogens
Progestogens (e.g. megestrol acetate, hydroxyprogesterone and medrogestone) exert their testosterone-depressing action by inhibition of LH release and blockade of androgen receptors. This decreases testosterone levIes in the serum and blocks the action of testosterone, causing a reduction in prostatic volume.
In 1975, Donkervoort et al. published a doubleblind study comparing megestrol acetate 250mg 3 times a day with placebo for 16 weeks in 36 patients with BPH. No significant change in symptoms was found compared with baseline values in either group. Urodynamic investigations suggested a positive effect in megestrol acetate recipients, but no significant change could be demonstrated. However, 7 of those receiving active treatment complained of loss of libido, compared with 2 in the placebo group. Geller et al. (1979) reported a placebo-controlled study of megestrol acetate 40mg 3 times a day in 61 patients. Compared with baseline values, the patients treated with megestrol acetate demonstrated significant increases in mean and peak urinary flow rates from the sixth week of treatment. No significant changes in urinary flow were observed in the placebo group. Relative to the placebo group, urinary peak flow rate increased to a statistically significant level in the megestrol acetate group after 20 weeks of therapy. Symptomatic improvement was noticed in 78% of megestrol acetate recipients vs 57% with placebo. 12 of 17 patients receiving megestrol acetate reported loss of libido during treatment compared with 5 of 12 placebo recipients.
Adverse affects such as decreased libido and impotence have kept progestogens from common use in BPH treatment.
Flutamide
Flutamide is a nonsteroidal antiandrogen that competes with DHT for cytosolic androgen receptor sites in the prostate cells. Flutamide does not substantially change sexual potency and libido as progestogens and GnRH agonists do. Adverse effects include gynaecomastia and diarrhoea. Caine et al. (1975b) reported the effects of flutamide 100mg 3 times daily in a double-blind, placebo-controlled study of 31 men with BPH, of whom all but one completed the study. Mean and peak urinary flow rates improved to a statistically significant degree in flutamide vs placebo recipients. No definite change in prostatic size between the flutamide and placebo groups was observed by bimanual palpation of the prostate, and this was matched by no definable changes in prostatic symptoms. Nipple pain and gynaecomastia were reported in 7 of 15 patients in the flutamide-treated group.
In a further study investigating flutamide in BPH, Stone (1989) reported results obtained in 84 patients with BPH who were enrolled and prospectively randomised to receive flutamide 750 mg/day (n = 42) or placebo (n = 42) in a double-blind fashion. 30 of the patients received placebo and 28 flutamide for 12 weeks, 4 and 8 of whom, respectively, went on to complete 6 months of treatment.
No change in prostatic volume was observed in the placebo group. An average decrease in prostatic volume of 18 and 41 % was observed in the flutamide group after 3 and 6 months of treatment, respectively, and this was associated with increases in peak urinary flow rate of 30 and 35%. Although no changes from baseline values were observed in the placebo recipients, both groups reported a significant decrease in severity of urinary symptoms.
Adverse effects were also reported in both groups: 40% in the placebo-and 69% in the flutamide-treated patients. Adverse effects associated with flutamide were breast pain, gynaecomastia and diarrhoea. Change in libido or impotence were not reported during flutamide treatment. As described above, testosterone is converted to DHT by the enzyme Sa-reductase. ImperatoMcGinley et al. (1974) described the syndrome of spontaneous Sa-reductase deficiency in men, characterised by pseudohermaphroditism; manifestations of the disease include small to absent prostates. Even with increasing age, the prostate is not palpable at rectal examination. However, these individuals are sexually potent and able to ejaculate. Blockade of Sa-reductase results in regression of BPH or, theoretically, prevention of development of BPH if given early enough.
Finasteride is a 4-aza-steroid compound with a specific Sa-reductase enzyme-blocking effect, which has been proven to reduce DHT levels significantly at a dosage of 0.2mg orally once daily (Peters & Sorkin 1993; Stoner 1990 ). Finasteride does not affect the binding of testosterone to androgen receptors. It can be given orally and has in itself no androgenic, antiandrogenic or other steroid hormone-related properties. Serum testosterone levels increase significantly but to a clinically unimportant degree during finasteride treatment (Stoner 1990 ).
Efficacy
In 1992, Stoner et al. published the results of two trials with finasteride. In the first double-blind study 86 patients with BPH were treated with finasteride 5 to 80mg or placebo for 12 weeks, followed by a 12-week drug-free period.
After 12 weeks of treatment, a significant decrease in prostatic volume compared with baseline was observed vs no significant change with placebo. In those receiving finasteride, the decrease in prostatic volume was 9 to 22.8%. However, after 24 weeks, shrinkage of the prostate volume was only present in the 5mg-and 40mg-treated groups.
The second trial reported was a double-blind, parallel group, placebo-controlled study of 104 patients, who were randornised to receive finasteride 0.2,0.5, 1,5, 40mg or placebo every morning for 24 weeks, following a I-week placebo run-in.
Compared with baseline values, a significant increase in peak urinary flow rates of 3.7 ml/sec between the placebo group and the groups of patients receiving finasteride 1 or 5mg (pooled together) was observed.
With respect to urinary symptoms, the authors found a significant decrease in total symptom scores after 10 weeks of treatment and throughout the investigation period when comparing the placebo group with the groups receiving finasteride 1 and 5mg. No significant differences between the low dose finasteride and placebo groups were observed. Significant or near significant changes in mean obstructive scores occurred in recipients of finasteride 1 and 5mg compared with placebo from weeks 7 to 24. Irritative symptoms did not differ between active drug and placebo, except for between weeks 16 through to 20 in patients receiving 1 or 5mg.
The most common reported adverse effect was headache. 14 serious adverse events were reported, 13 among the finasteride-treated patients. Unfortunately, only 4 of these were detailed in the published study. These were 3 episodes of prostate cancer and 1 episode of atrial fibrillation.
In 1992 the Finasteride Study Group (Gormley et al. 1992) reported the results of a multicentre study involving 895 men treated with finasteride 1 or 5 mg/day or placebo for 12 months.
Significant increases in urinary flow rates of 1.6 and 1.4 mllsec were observed in the 5-and 1mg-treated groups compared with baseline values, respectively. No significant change in urinary flow rates was observed in the placebo-treated group. Prostatic volume was decreased by approximately 20% after 12 months of treatment in the two finasteride-treated groups. No significant change in prostate volume was found in the placebo group, and at all times the difference in the percentage of men with reduction in prostate volume receiving active drug or placebo was at least 20%. The main change in prostatic volume was observed during the first 6 months of treatment after which no further significant change was found.
With respect to urinary symptoms, a significant reduction in total, obstructive and nonobstructive scores was observed in patients receiving finasteride 5mg compared with placebo. In those receiving 1mg, a significant decrease in obstructive but not in total and nonobstructive symptoms occurred.
Adverse effects were similar in the 3 groups, except for a significantly higher incidence of decreased libido (6 and 4.7% vs 1.7% in finasteride 1 and 5mg groups vs placebo group, respectively), impotence (3.4 and 5% vs 1.7%) and ejaculatory disorders (4.4 and 4.4% vs 1.7%.
Tolerability
Most commonly reported adverse effects with finasteride are impotence, decreased libido and reduced ejaculate volume. However, reduced sexual function due to finasteride treatment is not nearly as commonly seen as with other androgen-suppressing drugs.
Dosage and Administration
The recommended dosage of finasteride is 5mg daily. The drug may need to be taken for 6 months or more to exert maximum effects.
Finasteride is now approved by the FDA for treatment of BPH, but has only been in general clinical use for 2 years. Only further follow-up trials in larger patient popUlations will show whether finasteride will gain wide acceptance in the treatmentofBPH.
Summary of Androgen-Suppressing Therapy
Antiandrogen therapy for BPH is focused on symptom relief through reduction in prostate volume. Effective androgen suppression appears to reduce prostatic volume by 20 to 40% over 3 to 6 months of therapy (McConnell 1990) . Antiandrogen therapies cause clinical and urodynamic improvements, but do not reach the efficacy of TURP, which is still considered the 'gold standard' treatment for this disorder.
However, the thesis which equated reduction in prostatic size with relief of symptoms may not prove to be correct. Other mechanisms may be part of the symptomatic relief experienced with these drugs. Detailed morphometric and urodynamic investigations of anti androgen-treated patients are needed to provide insight into this point (McConnell 1990) .
With the exception of finasteride, the trials investigating antiandrogen therapy often show the same weakness as the studies evaluating a-receptor blockers -few patients, no follow-up and lack of placebo controls, no evaluation of quality of life and sexual function. More recent studies, however, contain all these items, including a validated questionnaire (Gormley et al. 1992) .
Treatment Recommendations
Drug therapy for BPH is indicated in patients with moderate symptoms of bladder outlet obstruction, for whom a strong indication for surgery, such as urinary retention, does not exist. Further, patients with recurrent severe gross haematuria, as well as urinary tract infections resistant to antimicrobial therapy, uraemia with hydronephrosis or overflow incontinence, are all candidates for TURP or other standard surgery. Cystoscopic findings or an enlarged prostate represent weak indications for any kind of intervention or therapy.
In patients with moderate symptoms of bladder outlet obstruction, the differentiation between surgery and, medical treatment is often difficult. Any kind of surgical procedure is associated with a certain morbidity. On the other hand, drug therapy may be associated with significant adverse effects. Furthermore, a lifetime of treatment with any drug or combination of drugs will be a major economic burden for both patient and society. Nevertheless, some BPH patients need long term treatment for diseases other than BPH. Thus, a younger patient with mild symptoms of BPH, arterial hypertension and elevated blood lipids might benefit from a-receptor blocker treatment.
When considering which pharmacological approach to take, the physician and patient must realise that the clinical benefit of antiandrogen therapy might take 6 to 12 months or even longer. The effect of a-receptor blockers will usually start ap-79 proximately 2 to 4 weeks after institution of therapy. Patients seeking prompt symptom relief might be candidates for a-blocker therapy as opposed to antiandrogens. It appears that selective ai-receptor blockers have an advantage over nonselective areceptor blockers in terms of tolerability. Terazosin can be administered once daily, whereas prazosin needs to be given 2 or 3 times daily. Tamsulosin and doxazosin are still under clinical investigation.
Finasteride seems to be the best tolerated and most effective agent of all antiandrogen drugs for BPH. However, the results of long term therapy with finasteride are not yet available. During institution offinasteride treatment, a declining prostate specific antigen (PSA) level is noted. I Patients who are candidates for, and prefer, this medical modality for BPH should have a well established baseline PSA value. In spite of this fact, substantial problems in the screening for prostate cancer might be observed in these patients.
A combination of a-receptor blockade and androgen suppression may be a new and appealing approach in BPH drug treatment. Trials investigating and comparing different combinations of drugs are underway, but the results of these are currently not available.
The future challenge is to administer treatment to only those patients who are likely to experience a beneficial and substantial effect of therapy at the lowest costs and morbidity possible.
PSA is a glycopeptide secreted exclusively by prostate epithelial tissue. It is used to both monitor response in the treatment of prostate cancer, and in the early detection and screening for this disease. However, PSA is not prostate cancer-specific, but prostate tissue-specific. Numerous benign prostate conditions can influence PSA serum levels. There are substantial problems in defining reliable criteria for detecting prostate cancer, and approximately 20% of patients with BPH have PSA levels >41lg/L. Values between o and 4 Ilg/L are usually considered as being within the normal range.
